BR0014331A - Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença - Google Patents
Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doençaInfo
- Publication number
- BR0014331A BR0014331A BR0014331-6A BR0014331A BR0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A BR 0014331 A BR0014331 A BR 0014331A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- chain
- synthesizing enzyme
- optionally substituted
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title abstract 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title abstract 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940031439 squalene Drugs 0.000 title abstract 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title abstract 3
- 230000002194 synthesizing effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940125532 enzyme inhibitor Drugs 0.000 title abstract 2
- 239000002532 enzyme inhibitor Substances 0.000 title abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- -1 QUINUCLIDINE COMPOUND Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, INIBIDOR DE ENZIMA SINTETIZADORA DE ESQUALENO, COMPOSIçãO MEDICINAL, PROCESSO PARA A PRODUçãO DE UM COMPOSTO QUINUCLIDìNICO E PROCESSO PARA PREVENçãO OU CURA DE UMA DOENçA". A presente invenção proporciona um inibidor excelente para a enzima sintetizadora de esqualeno. Especificamente, ela apresenta um composto (I), representado por meio da fórmula que se segue, um de seus sais ou hidratos. Na qual R^ 1^ representa (1) um átomo de hidrogênio ou (2) um grupo hidroxila; HAr representa um heterociclo aromático que pode estar substituído com 1 a 3 grupos; Ar representa um anel aromático opcionalmente substituído; W significa uma cadeia representada por (1) -CH~ 2~CH~ 2~-, que pode estar substituída, (2) -CH=CH-, que pode estar substituída, (3) C<154>C-, (4) -NH-CO-, (5) -CO-NH-, (6) -NH-CH~ 2~-, (7) -CH~ 2~-NH-, (8) -CH~ 2~-CO-, (9) -CO-CH~ 2~-, (10) -NH-S(O)~ 1~-, (11) -S(O)~ 1~-NH-, (12) -CH~ 2~-S(O)~ 1~-, ou (13) -S(O)~ 1~-CH2-, (em que 1 representa 0, 1 ou 2); e X significa uma cadeia representada por meio de (1) uma ligação simples, (2) uma cadeia alquilênica C~ 1-6~, opcionalmente substituída, (3) uma cadeia alquenilênica C~ 2-6~, opcionalmente substituída, (4) uma cadeia alquinilênica C~ 2-6~,opcionalmente substuída, (5) uma fórmula -Q- (em que Q representa um átomo de oxigênio, um átomo de enxofre, CO ou N (R^ 2^ ) (em que R^ 2^ representa um grupo alquila C^ 1-6^ ou um grupo alcoxi C^ 1-6^, (6) -NH-CO-, (7) -CO-NH-, (8) -NH-CH^ 2^-, (9) -CH^ 2^-NH-, (10) -CH^ 2^-CO-, (11) -CO-CH~ 2~, (12) -NH-S(O)~ m~-, (13) -S(O)~ m~-NH-, (14) -CH~ 2~-S (O)~ m~-, (15) -S (O)~ m~-CH^ 2^-, (em que m representa 0, 1 ou 2) ou (16) - (CH~ 2~)~ n~-O- (em que n representa um inteiro de 1 a 6).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27390599 | 1999-09-28 | ||
| JP2000179352 | 2000-06-15 | ||
| PCT/JP2000/006665 WO2001023383A1 (fr) | 1999-09-28 | 2000-09-27 | Composes de quinuclidine et medicaments contenant ces composes comme principe actif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014331A true BR0014331A (pt) | 2003-06-10 |
Family
ID=26550809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014331-6A BR0014331A (pt) | 1999-09-28 | 2000-09-27 | Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6599917B1 (pt) |
| EP (1) | EP1217001B1 (pt) |
| JP (1) | JP4206212B2 (pt) |
| KR (1) | KR100694687B1 (pt) |
| CN (1) | CN100334085C (pt) |
| AT (1) | ATE312100T1 (pt) |
| AU (1) | AU782114B2 (pt) |
| BR (1) | BR0014331A (pt) |
| CA (1) | CA2385995C (pt) |
| DE (1) | DE60024651T2 (pt) |
| DK (1) | DK1217001T3 (pt) |
| ES (1) | ES2252063T3 (pt) |
| HU (1) | HUP0203514A3 (pt) |
| IL (2) | IL148631A0 (pt) |
| MX (1) | MXPA02003167A (pt) |
| NO (1) | NO328218B1 (pt) |
| NZ (1) | NZ517788A (pt) |
| RU (1) | RU2266905C2 (pt) |
| TW (1) | TWI282794B (pt) |
| WO (1) | WO2001023383A1 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| EP1375496B1 (en) * | 2001-03-27 | 2007-07-04 | Eisai R&D Management Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| EP1256573A1 (en) | 2001-05-09 | 2002-11-13 | Eisai Co., Ltd. | Process for producing stereoisomer of pyrrolidine derivative |
| NZ532283A (en) | 2001-10-17 | 2005-06-24 | Ucb S | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| US7361671B2 (en) * | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| DE10225537A1 (de) * | 2002-06-10 | 2003-12-18 | Bayer Ag | N-alkylierte Thiazoliumsalze und Verfahren zu deren Herstellung |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| PL210065B1 (pl) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| JP4667384B2 (ja) * | 2003-10-07 | 2011-04-13 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
| KR101176670B1 (ko) | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| AU2011258005A1 (en) | 2010-05-28 | 2013-01-17 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as Janus kinase inhibitors |
| PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| BR112015009751A2 (pt) | 2012-10-31 | 2017-07-11 | Bayer Cropscience Ag | novos compostos heterocíclicos como pesticidas |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| AU2016273751B2 (en) | 2015-06-03 | 2020-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| GB9127279D0 (en) | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
| JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| GB9207961D0 (en) | 1992-04-10 | 1992-05-27 | Ici Plc | Heterocyclic derivatives |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| AU7394394A (en) | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
| GB9226573D0 (en) * | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
| IL109451A0 (en) | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| GB9412145D0 (en) | 1994-06-17 | 1994-08-10 | Zeneca Ltd | Heterocycles |
| JPH08134067A (ja) | 1994-11-11 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| JPH08269056A (ja) | 1995-03-29 | 1996-10-15 | Chugai Pharmaceut Co Ltd | スクアレンシンセターゼ阻害作用を有するキヌクリジン誘導体 |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| JP2000511532A (ja) * | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
-
2000
- 2000-09-27 EP EP00962889A patent/EP1217001B1/en not_active Expired - Lifetime
- 2000-09-27 WO PCT/JP2000/006665 patent/WO2001023383A1/ja active IP Right Grant
- 2000-09-27 MX MXPA02003167A patent/MXPA02003167A/es active IP Right Grant
- 2000-09-27 CA CA002385995A patent/CA2385995C/en not_active Expired - Fee Related
- 2000-09-27 IL IL14863100A patent/IL148631A0/xx unknown
- 2000-09-27 AU AU74464/00A patent/AU782114B2/en not_active Ceased
- 2000-09-27 DK DK00962889T patent/DK1217001T3/da active
- 2000-09-27 US US10/088,554 patent/US6599917B1/en not_active Expired - Fee Related
- 2000-09-27 RU RU2002111344/04A patent/RU2266905C2/ru not_active IP Right Cessation
- 2000-09-27 ES ES00962889T patent/ES2252063T3/es not_active Expired - Lifetime
- 2000-09-27 TW TW089119958A patent/TWI282794B/zh not_active IP Right Cessation
- 2000-09-27 HU HU0203514A patent/HUP0203514A3/hu unknown
- 2000-09-27 CN CNB00813541XA patent/CN100334085C/zh not_active Expired - Fee Related
- 2000-09-27 DE DE60024651T patent/DE60024651T2/de not_active Expired - Lifetime
- 2000-09-27 AT AT00962889T patent/ATE312100T1/de not_active IP Right Cessation
- 2000-09-27 NZ NZ517788A patent/NZ517788A/en not_active IP Right Cessation
- 2000-09-27 BR BR0014331-6A patent/BR0014331A/pt not_active Application Discontinuation
- 2000-09-27 JP JP2001526535A patent/JP4206212B2/ja not_active Expired - Fee Related
- 2000-09-27 KR KR1020027003952A patent/KR100694687B1/ko not_active IP Right Cessation
-
2002
- 2002-03-12 IL IL148631A patent/IL148631A/en not_active IP Right Cessation
- 2002-03-26 NO NO20021528A patent/NO328218B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU782114B2 (en) | 2005-07-07 |
| NZ517788A (en) | 2003-11-28 |
| DE60024651T2 (de) | 2006-09-28 |
| DK1217001T3 (da) | 2006-03-20 |
| CA2385995C (en) | 2009-06-16 |
| HUP0203514A3 (en) | 2004-01-28 |
| ES2252063T3 (es) | 2006-05-16 |
| CN100334085C (zh) | 2007-08-29 |
| NO20021528L (no) | 2002-05-28 |
| NO328218B1 (no) | 2010-01-11 |
| KR20020034197A (ko) | 2002-05-08 |
| IL148631A0 (en) | 2002-09-12 |
| EP1217001A4 (en) | 2002-12-18 |
| KR100694687B1 (ko) | 2007-03-13 |
| MXPA02003167A (es) | 2003-10-06 |
| NO20021528D0 (no) | 2002-03-26 |
| WO2001023383A1 (fr) | 2001-04-05 |
| RU2266905C2 (ru) | 2005-12-27 |
| US6599917B1 (en) | 2003-07-29 |
| TWI282794B (en) | 2007-06-21 |
| AU7446400A (en) | 2001-04-30 |
| ATE312100T1 (de) | 2005-12-15 |
| DE60024651D1 (de) | 2006-01-12 |
| JP4206212B2 (ja) | 2009-01-07 |
| CN1377349A (zh) | 2002-10-30 |
| CA2385995A1 (en) | 2001-04-05 |
| EP1217001B1 (en) | 2005-12-07 |
| IL148631A (en) | 2010-04-29 |
| EP1217001A1 (en) | 2002-06-26 |
| HUP0203514A2 (hu) | 2003-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0014331A (pt) | Composto, inibidor de enzima sintetizadora de esqualeno, composição medicinal, processo para produção de um composto quinuclidìnico e processo para prevenção ou cura de uma doença | |
| BR0114436A (pt) | Composto com anel de cinco elementos contendo nitrogênio alifático | |
| BRPI0616393B8 (pt) | compostos heterocíclicos fundidos úteis como moduladores de quinase, composição farmacêutica e usos dos mesmos | |
| PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
| BR0015466A (pt) | Composto, prodroga, composição farmacêutica, agentes para evitar ou tratar diabetes mellitus, hiperlipidemia e toler ncia à glicose prejudicada, para regular a função do receptor relacionado a retinóide e para melhorar a resistência à insulina e uso de um composto | |
| BR9812095A (pt) | Compostos de indol como inibidores de cox-2 | |
| BR9813835A (pt) | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica | |
| BR0212378A (pt) | Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio | |
| BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
| BR0316991A (pt) | Compostos de anel de 1,3-diidro-imidazol fundido | |
| BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
| BRPI0810524B8 (pt) | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado | |
| BRPI0511722A (pt) | 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina | |
| BR112012007069A2 (pt) | derivado de fenol | |
| BRPI0406721A (pt) | Compostos condensados de furano | |
| BR9712134A (pt) | cidos hiidroxâmicos de b-sulfonila como inibidores de metaloproeinases de matriz. | |
| BRPI0408338A (pt) | piperidinas substituìdas como novos inibidores de mdm2-p53 | |
| BR0310032A (pt) | Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos | |
| BRPI0602132A (pt) | compostos de indanil-piperazina, processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| UY25114A1 (es) | Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. | |
| BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
| BR0311410A (pt) | Composto de piperidina | |
| CO5700712A2 (es) | Prevencion y tratamiento de la enfermedad de alzheimer | |
| BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b | |
| BR0104471A (pt) | Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: EISAI R AND D MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07D 453/02; A61K 31/4545; A61K 31/444; A61K 31/506; A61K 31/439; A61P 43/00; A61P 3/06; A61P 9/10; C07M 7/00. Ipc: C07D 453/02 (2006.01) Ipc: C07D 453/02 (2006.01) |